| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Apr 20, 2026 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Haisco–AbbVie $745M Deal Targets Global Pain
|
|
| | Interna–Daiichi Pact Targets Intracellular Tech
|
|
| | Avanos $1.27B Take-Private Deal with AIP
|
|
| | PharmaShots Awards Set for May 1: Celebrating Industry Excellence
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
Telix–Regeneron $2.1B Radiopharma Alliance
|
| |
Strategic Collaborations
|
| |
| • | Haisco–AbbVie Pain Therapeutics Deal
|
|
| • | Interna–Daiichi Sankyo Intracellular Delivery Pact
|
|
| • | Aligos–Amoytop HBV Alliance (Greater China)
|
|
| • | Piramal–Ajinomoto ADC Collaboration
|
|
| |
Divestment
|
| |
| • | CareDx $170M Lab Business Sale to Eurobio Scientific
|
|
| |
M&A Activity
|
| |
| • | Avanos $1.27B Take-Private by American Industrial Partners
|
|
| • | Eli Lilly Acquires CrossBridge Bio (Dual-Payload ADCs)
|
|
| |
Clinical Trials Spotlight
|
| |
| • | HER2+ Endometrial Cancer (BioNTech ADC Data)
|
|
| • | r/r CLL/SLL (Eli Lilly Jaypirca Regimen)
|
|
| • | TGCT (SynOx Emactuzumab Phase III)
|
|
| • | Type 2 Diabetes CV Risk (Eli Lilly Orforglipron)
|
|
| • | Brain Metastases Imaging (Radiopharm RAD101)
|
|
| |
Regulatory Updates
|
| |
| • | Regeneron Pharmaceuticals / Sanofi Dupixent EU Approval (CSU)
|
|
| • | Daiichi Sankyo / Merck & Co. Priority Review (I-DXd)
|
|
| • | Multiple FDA, NMPA, Health Canada, Swissmedic Updates
|
|
| |
MedTech
|
| |
| • | Miracell PRP Systems FDA Clearance
|
|
| • | Protaryx Transseptal Device Clearance
|
|
| • | TOBY Multi-Cancer Test Breakthrough Status
|
|
| • | QIAGEN BCID Panel Launch
|
|
| • | Cala Health kIQ Plus Clearance
|
|
| • | Philips Spectral CT Clearance
|
|
| |
|
| |
|
| |
Innovation. Leadership. Breakthroughs.
|
| |
The global pharmaceutical and healthcare landscape is evolving at an unprecedented pace, driven by visionary leadership, cutting-edge science, and technologies that are redefining patient care.
|
| |
PharmaShots Awards 2026 is your front-row seat to this transformation—a premier virtual event honoring the organizations and leaders who are pushing the boundaries of innovation across the life sciences ecosystem.
|
| |
From drug discovery and biopharma breakthroughs to medtech, diagnostics, and digital health, these awards celebrate the pioneers shaping the future of healthcare and driving real-world impact.
|
| |
Awards Announcement: May 1, 2026
Virtual Global Event: Register Here
|
| |
Join industry leaders, innovators, and decision-makers worldwide to recognize excellence, vision, and the breakthroughs that are changing lives. Every achievement that transforms healthcare deserves to be celebrated.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form here
|
| |
|
| |
|
| |
Telix–Regeneron Forge $2.1B Radiopharma Alliance to Redefine Precision Oncology & Pain Care
|
| |
|
| |
Telix Pharmaceuticals and Regeneron Pharmaceuticals have entered a landmark strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, initially focused on multiple solid tumor targets and broader precision oncology applications.
|
| |
Why It Matters
|
| |
| • | Deal Value: $40M upfront plus up to ~$2.1B in aggregate development and commercial milestones across the first four programs, alongside low double-digit royalties when Telix opts out of co-funding.
|
|
| • | Flexible Economics: Per-program choice between 50/50 cost/profit share or a milestone-and-royalty model gives Telix capital allocation flexibility.
|
|
| • | Integrated Theranostics: Joint development of radiopharmaceutical therapeutics and companion radio-diagnostics supports true precision oncology—optimizing patient selection and longitudinal response assessment.
|
|
| |
Strategic Focus
|
| |
| • | Platform Synergy: Marries Telix’s radiolabeling and manufacturing infrastructure with Regeneron’s antibody and bispecific discovery engines (VelocImmune and VelociSuite) to generate a pipeline of antibody-based radiopharmaceuticals.
|
|
| • | Solid Tumor Ambition: Initial focus on multiple solid tumor targets from Regeneron’s antibody portfolio positions the alliance at the forefront of radiopharma for hard-to-treat cancers.
|
|
| • | Global Co-Development: Equal sharing of development costs and profits for co-funded programs aligns incentives and de-risks large, multi-asset investment for both parties.
|
|
| • | Diagnostic Leadership: Telix leads commercialization of radio-diagnostics while Regeneron participates in defined profit share, reinforcing Telix’s position as a theranostics leader.
|
|
| |
|
| |
| | Global Biopharma Alliances Drive Next-Gen Innovation
|
|
|
|
|
| |
Haisco–AbbVie Alliance Ignites Global Ambitions in Next-Gen Pain Therapeutics
|
| |
|
| |
Haisco has entered an exclusive licensing agreement with AbbVie, granting AbbVie global rights—excluding mainland China, Hong Kong, and Macau—to develop, manufacture, and commercialize a portfolio of novel, non-opioid pain therapies.
|
| |
Why It Matters
|
| |
| • | Deal Value: $30M upfront plus up to $715M in milestones for a total potential value of $745M, plus tiered royalties.
|
|
| • | Geographic Split: AbbVie controls rights worldwide ex–mainland China, Hong Kong, and Macau, while Haisco retains its home-market opportunity.
|
|
| • | Pipeline Breadth: Covers multiple non-opioid pain programs from preclinical through Phase I, creating a multi-asset growth option set rather than a single-drug bet.
|
|
| |
Strategic Focus
|
| |
| • | AbbVie Pain Push: Strengthens AbbVie’s pain and neuroscience portfolio as it restocks beyond legacy assets and competitors’ NaV1.8 leads.
|
|
| • | Haisco Globalization: Validates Haisco as a source of globally competitive innovation and extends its footprint via a top-tier multinational partner.
|
|
| • | Patient Impact: Aims to advance differentiated, non-opioid pain therapies in an area of high unmet need and ongoing concerns around opioid safety and dependence.
|
|
| |
|
| |
Interna & Daiichi Sankyo Unite to Advance Next-Gen Intracellular Delivery Technologies
|
| |
Interna Therapeutics has entered a research collaboration with Daiichi Sankyo, through the Daiichi Sankyo Research Institute Boston, to evaluate Interna’s proprietary Molecular Nano Motor (MNM) technology as a next-generation intracellular delivery enhancer for targeted therapeutics.
|
| |
Why It Matters
|
| |
| • | Next-Gen Delivery: Addresses one of drug development’s core bottlenecks—efficient intracellular delivery of large and complex therapeutics.
|
|
| • | Platform Versatility: MNM can be adapted to a broad range of cargos and administration routes, expanding its utility across modalities.
|
|
| • | Expansion Path: Agreement includes a framework to broaden the collaboration into additional programs if early data are supportive.
|
|
| |
Strategic Focus
|
| |
| • | Daiichi Sankyo Innovation Push: Complements Daiichi Sankyo’s advances in ADCs and targeted therapies with a novel intracellular delivery engine.
|
|
| • | Interna Validation: Reinforces growing recognition of the MNM platform as a credible, scalable alternative to traditional delivery technologies.
|
|
| • | Patient Impact Potential: Improved intracellular delivery could unlock more potent and durable responses in diseases where current therapies fail to reach or modulate key intracellular targets effectively.
|
|
| |
|
| |
Aligos–Amoytop Alliance Accelerates HBV Innovation Across Greater China
|
| |
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting Amoytop rights to develop and commercialize pevifoscorvir sodium in Greater China (mainland China, Hong Kong, Macau, and Taiwan) for the treatment of chronic hepatitis B virus (HBV) infection.
|
| |
Why It Matters
|
| |
| • | Deal Value: $25M upfront plus up to ~$420M in milestones and tiered high single-digit royalties on Greater China net sales.
|
|
| • | Territorial Split: Amoytop leads development and commercialization in Greater China, while Aligos retains rights and global strategy for all other territories.
|
|
| • | Clinical Momentum: Phase IIb B-SUPREME is ongoing with positive first interim signals, second interim in H2 2026, and topline data expected in 2027.
|
|
| |
Strategic Focus
|
| |
| • | China-Centric Acceleration: Leverages Amoytop’s HBV commercial experience (including PEGBING) and regulatory presence in China to speed regional development.
|
|
| • | Global HBV Strategy: Allows Aligos to conserve capital while advancing pevifoscorvir globally, extending its cash runway into Q4 2026.
|
|
| • | Next-Generation HBV Therapy: Positions pevifoscorvir sodium as a potential backbone for future finite or functional cure–oriented HBV regimens.
|
|
| |
|
| |
Piramal–Ajinomoto Alliance Powers Next-Gen ADC Innovation at Global Scale
|
| |
|
| |
Piramal Pharma Solutions has formed a strategic collaboration with Ajinomoto Bio-Pharma Services to accelerate antibody-drug conjugate (ADC) development and manufacturing programs globally.
|
| |
Why It Matters
|
| |
| • | Technology + Capacity: AJICAP delivers precise, site-specific conjugation without antibody re-engineering, while Piramal offers large-scale GMP manufacturing and global CDMO reach.
|
|
| • | Bidirectional Referrals: Structured referral model ensures innovators can access best-in-class conjugation tech and manufacturing under a coordinated framework.
|
|
| • | Faster Scale-Up: MTA-enabled tech transfer is designed to accelerate transition from development to commercial production, reducing tech-transfer friction.
|
|
| |
Strategic Focus
|
| |
| • | End-to-End ADC Solutions: Positions the alliance as a one-stop ecosystem for ADC innovators—from target molecule and linker selection through clinical and commercial supply.
|
|
| • | Quality and Consistency: AJICAP’s site-specific chemistry supports highly consistent drug-to-antibody ratios, which, combined with Piramal’s quality systems, can enhance product robustness.
|
|
| • | Global Biopharma Support: Aims to serve both emerging and established biopharma companies seeking to rapidly advance differentiated ADC pipelines worldwide.
|
|
| |
|
| |
| | CareDx $170M Divestiture Sharpens Strategic Focus
|
|
|
|
|
| |
CareDx Sharpens Strategic Focus with $170M Divestiture to Eurobio Scientific
|
| |
|
| |
CareDx has entered into a definitive agreement to divest its Lab Products business to Eurobio Scientific.
|
| |
Why It Matters
|
| |
| • | Deal Value: $170M all-cash consideration at closing for the Lab Products business.
|
|
| • | Portfolio Shift: Exits capital- and inventory-intensive lab products to double down on higher-margin testing services and digital health offerings.
|
|
| • | Strategic Rights: Retains exclusive North America distribution of post-transplant monitoring IVDs, including AlloSeq cfDNA, preserving a key revenue and strategic channel.
|
|
| |
Strategic Focus
|
| |
| • | Core Growth Emphasis: Aligns resources behind U.S. testing services, where CareDx is seeing strong volume and revenue growth.
|
|
| • | Partner-Leveraged Global Reach: Positions Eurobio/GenDx as a global leader in transplant genomics lab kits while CareDx continues to serve North American labs through distribution.
|
|
| • | Capital Allocation: Proceeds enhance CareDx’s ability to invest in innovation, potential inorganic expansion, and shareholder value initiatives.
|
|
| |
|
| |
| | Avanos Take-Private & Lilly Buyout Drive M&A
|
|
|
|
|
| |
Avanos Medical to Go Private in $1.27B All-Cash Take-Private with American Industrial Partners
|
| |
|
| |
Avanos Medical has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valuing the company at approximately $1.272B in enterprise value.
|
| |
Why It Matters
|
| |
| • | Deal Value: ~$1.272B enterprise value with $25 per share in cash for Avanos shareholders.
|
|
| • | Premium: Purchase price reflects a ~72.1% premium to Avanos’ closing share price on April 13, 2026, and an even higher premium to its 30-day VWAP.
|
|
| • | Timeline: Closing anticipated in H2 2026, pending shareholder approval and regulatory clearances; the deal is not subject to a financing condition.
|
|
| |
Strategic Focus
|
| |
| • | Go-Private Rationale: Private ownership under AIP is expected to provide additional strategic and operational flexibility for Avanos to pursue its long-term growth agenda.
|
|
| • | Operational Continuity: Headquarters and core operations remain in Alpharetta, Georgia, ensuring continuity for customers and employees.
|
|
| |
|
| |
Lilly Bets on Dual-Payload ADCs with CrossBridge Bio Buyout
|
| |
|
| |
Eli Lilly has entered into a definitive agreement to acquire CrossBridge Bio, adding a synergistic dual-payload antibody-drug conjugate (ADC) platform designed to deliver differentiated oncology therapeutics.
|
| |
Why It Matters
|
| |
| • | Deal Value: Up to ~$300M in total cash consideration, including upfront and milestone components.
|
|
| • | Mechanistic Edge: Dual-payload design leverages synthetic lethality—TOP1i induces replication stress while ATRi blocks the tumor’s DNA damage response.
|
|
| • | Pipeline Fit: Strengthens Lilly’s growing ADC and oncology portfolio with a next-generation TROP2-targeting asset.
|
|
| |
Strategic Focus
|
| |
| • | Next-Gen ADC Strategy: Builds on Lilly’s broader push into advanced ADC modalities beyond single-payload constructs.
|
|
| • | Resistance Management: CBB-120 is engineered to address resistance mechanisms emerging with first-wave TROP2 ADCs like sacituzumab govitecan.
|
|
| • | Clinical Acceleration: IND planned for 2026 positions CBB-120 to enter the clinic quickly under Lilly’s development infrastructure.
|
|
| |
|
| |
| | Clinical Wins Across Oncology, CV & Imaging Trials
|
|
|
|
|
| |
Phase II cohort data for trastuzumab pamirtecan (BNT323/DB-1303)
|
| |
|
| |
HER2-Expressing Recurrent Endometrial Cancer
|
| |
BioNTech reports positive Phase II cohort data for trastuzumab pamirtecan (BNT323/DB-1303) in HER2-expressing recurrent endometrial cancer, meeting the primary endpoint of ORR.
|
| |
Key Details
|
| |
| • | Cohort (n=145): confirmed ORR 47.9% in centrally HER2-tested patients (n=96) and 49.3% in checkpoint inhibitor–pretreated patients (n=73), with median PFS of 8.1 months and consistent efficacy across HER2 IHC 1+/2+/3+ expression levels.
|
|
| |
Next Steps
A global Phase III trial in advanced endometrial cancer is ongoing, with a BLA submission planned for 2026.
|
| |
Asset Snapshot
HER2-targeted ADC with clinically meaningful antitumor activity and a manageable safety profile, advancing toward late-stage registration.
|
| |
|
| |
r/r CLL/SLL
|
| |
|
| |
Eli Lilly reports positive Phase III BRUIN CLL-322 data for Jaypirca (pirtobrutinib) + venetoclax/rituximab vs. venetoclax/rituximab alone in relapsed/refractory CLL/SLL, using a fixed ~2-year treatment period followed by therapy-free observation until progression.
|
| |
Key Details
|
| |
| • | Primary endpoint met: Jaypirca triplet significantly improved PFS by IRC vs. venetoclax/rituximab, with consistent benefit across clinically relevant subgroups and irrespective of prior covalent BTK inhibitor exposure.
|
|
| • | OS data remain immature but currently trend in favor of the Jaypirca arm.
|
|
| |
Next Steps
Detailed results will be presented at an upcoming medical meeting and submitted to regulators later this year to support label expansion.
|
| |
Asset Snapshot
Highly selective non-covalent BTK inhibitor enabling a time-limited, triplet regimen that deepens responses beyond venetoclax/rituximab alone in r/r CLL/SLL.
|
| |
|
| |
TGCT (Tenosynovial Giant Cell Tumor)
|
| |
SynOx Therapeutics reports global Phase III TANGENT data for emactuzumab (1000 mg Q2W ×5 doses over 8 weeks) vs. placebo in TGCT, with 6 months of blinded treatment followed by 18 months’ follow-up and optional open-label emactuzumab at progression.
|
| |
Key Details
|
| |
| • | TANGENT met primary and secondary endpoints with high statistical significance, improving ORR by RECIST v1.1 and Tumor Volume Score, alongside clinically meaningful gains in PROMIS-PF, physical function, pain, range of motion, and stiffness.
|
|
| • | Short-course emactuzumab produced rapid, sustained, and durable clinical benefits across clinically relevant patient subgroups, with a manageable safety profile.
|
|
| |
Next Steps
Full TANGENT data will be presented at a medical meeting and published in a journal; SynOx plans a BLA submission to the FDA in H2 2026, followed by an EU MAA.
|
| |
Asset Snapshot
CSF-1R–targeting mAb positioned as a differentiated, finite-course alternative to chronic therapy in TGCT.
|
| |
|
| |
Type 2 Diabetes with High CV Risk
|
| |
|
| |
Eli Lilly reports positive Phase III ACHIEVE-4 topline data for Foundayo (orforglipron) vs. insulin glargine in ~2,700 adults with type 2 diabetes plus obesity/overweight and elevated cardiovascular risk, meeting the primary endpoint of MACE-4 non-inferiority.
|
| |
Key Details
|
| |
| • | Foundayo showed a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 vs. insulin glargine, with a 57% reduction in all-cause mortality (HR 0.43).
|
|
| • | At Week 52, Foundayo achieved greater A1C reduction (−1.6% vs. −1.0%) and body-weight change (−8.8% vs. +1.7%) vs. insulin glargine, with a GLP-1–class–consistent safety profile and no hepatic safety signal.
|
|
| |
Next Steps
Lilly plans to submit the ACHIEVE-4 data in an NDA to the US FDA by the end of Q2 2026.
|
| |
Asset Snapshot
Daily oral GLP-1 receptor agonist delivering robust glycemic, weight, and CV-risk benefits as an alternative to basal insulin in high-risk T2D.
|
| |
|
| |
Recurrent Brain Metastases (Imaging)
|
| |
|
| |
Radiopharm Theranostics has fully enrolled its U.S. Phase IIb imaging trial of RAD 101 (18F-RAD101) in 30 patients with recurrent brain metastases from solid tumors, with primary endpoint readout expected in June 2026 and plans to advance into a U.S. Phase III pivotal trial.
|
| |
Key Details
|
| |
| • | Phase IIb evaluates concordance between 18F-RAD101 PET and gadolinium-enhanced MRI; interim analysis showed 90% concordance, meeting the primary endpoint.
|
|
| |
Next Steps
Primary endpoint readout will guide Phase III design and regulatory strategy for RAD 101 in brain metastasis imaging.
|
| |
Asset Snapshot
Small-molecule FASN-targeted PET tracer with FDA Fast Track designation, aiming to distinguish true tumor recurrence from treatment effects, including leptomeningeal disease.
|
| |
|
| |
| | Global Regulatory Wins Drive Biopharma Momentum
|
|
|
|
|
| |
Regulatory Momentum Builds Across Global Markets
|
| |
|
| |
From dermatology and rare diseases to oncology and immunology, this week has delivered a strong wave of regulatory momentum across global markets. Here’s a quick look at the latest approvals, priority reviews, and submissions shaping the healthcare landscape.
|
| |
| • | Regeneron Pharmaceuticals and Sanofi’s Dupixent (Dupilumab) received approval from the European Commission for Chronic Spontaneous Urticaria (CSU).
|
|
| • | Daiichi Sankyo and Merck & Co. received U.S. Food and Drug Administration Priority Review for Ifinatamab Deruxtecan (I-DXd) to treat ES-SCLC.
|
|
|
| • | Partner Therapeutics reported the US FDA sBLA submission of Bizengri for NRG1 fusion positive cholangiocarcinoma.
|
|
| • | AOP Health reported the US FDA approval of Rapiblyk (Landiolol) for pediatric patients with supraventricular tachycardia.
|
|
| • | ARS Pharmaceuticals reported Health Canada approval of neffy 2mg to treat Type I allergic reactions.
|
|
| • | LEO Pharma reported the US FDA’s sNDA acceptance of Anzupgo for use in children with chronic hand eczema.
|
|
| • | LEO Pharma’s Enstilar received NMPA approval for plaque psoriasis.
|
|
| • | Bavarian Nordic reported Swissmedic approval of Vimkunya to prevent chikungunya.
|
|
| |
|
| |
| | MedTech Innovations Gain Rapid Regulatory Momentum
|
|
|
|
|
| |
Global MedTech Progress Signals Faster Innovation
|
| |
|
| |
From AI-powered diagnostics to breakthrough devices and advanced imaging systems, the MedTech space continues to see rapid regulatory progress. Here’s a quick look at the latest clearances, designations, and launches shaping the future of medical technology.
|
| |
|
|
|
|
|
|
| |
|
| |
|
| |
Future Biotech Expo 2026 | June 02-03 | Hilton Houston North, TX, USA
|
| |
The Future Biotech Expo is a premier international red biotechnology exhibition and conference dedicated to accelerating breakthroughs across the industry vertical that are shaping the future of healthcare and medicine across the globe and beyond.
|
| |
Future Biotech Expo features a world-class exhibition, thought-provoking conferences, startup showcases, structured B2B matchmaking, and a dedicated Hosted Buyer Program ensuring meaningful engagement and global impact. At the Expo, you will be able to gain valuable insight and engage in conversations with over 3500+ industry pioneers and decision makers. The Future Biotech Expo will deliver an exclusive event experience for the participants to discover the latest technological advancements & groundbreaking offerings and simultaneously deliberate on the ways to widen the scope of red biotechnology across the globe.
|
| |
|
| |
|
| |
|
| |
Mega-Deals, Breakthrough Science, and Strategic Shifts Redefine Biopharma’s Next Frontier
|
| |
This week’s landscape is led by a $2.1B radiopharma alliance between Telix Pharmaceuticals and Regeneron Pharmaceuticals, alongside high-impact deals from AbbVie, Eli Lilly, and Daiichi Sankyo. From next-gen ADCs and intracellular delivery to HBV innovation and non-opioid pain therapies, partnerships dominate strategy. M&A and divestments signal sharper focus, while strong clinical and regulatory momentum across oncology, immunology, and MedTech underscores an industry accelerating toward precision, scalability, and global reach.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
The biopharma world never slows—breakthrough data drops overnight, billion-dollar deals shift competitive landscapes, and regulatory decisions can reshape entire markets in real time. In a sector moving at this speed, timely intelligence isn’t optional—it’s mission-critical.
|
| |
PharmaShots Weekly cuts through the noise, delivering only what matters: pivotal pipeline updates, regulatory milestones, clinical breakthroughs, strategic partnerships, and emerging competitive dynamics—distilled into a crisp, executive-ready briefing you can absorb in minutes.
|
| |
Every Monday at 8:00 AM EST, get a decision-focused snapshot of the forces shaping global pharma and biotech—curated for leaders who act on insight, not overload.
|
| |
If this edition sparked ideas, make it a habit. Subscribe to PharmaShots Weekly for intelligence that is concise, credible, and crafted for decision-makers across R&D, competitive intelligence, strategy, and business development.
|
| |
Know someone who values signal over noise? Forward this edition.
Spotted an insight worth amplifying? Share it on LinkedIn and tag PharmaShots—we love spotlighting sharp industry perspectives.
|
| |
The industry moves fast.
Your intelligence should move faster.
|
| |
| | Tell your success story to the world!
Reach out to us [email protected] for CXO Talks or Viewpoint interview, because your story matters!
|
|
|
|
|
| |
|
0 comments